Results 161 to 170 of about 2,510,208 (357)
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez+5 more
wiley +1 more source
This study compared the clinical effectiveness and treatment satisfaction of Pregabalin and Gabapentin triple therapy for neuropathic pain in a real‐world setting. The primary outcome measured the reduction in mean Self‐Administered Leeds Assessment of Neuropathic Symptoms and Signs pain score value from baseline to 12 weeks posttreatment.
Nithya Raju+7 more
wiley +1 more source
Opiate withdrawal syndrome mimicking postoperative intestinal obstruction [PDF]
Christian Macutkiewicz+4 more
openalex +1 more source
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen+10 more
wiley +1 more source
Abstract Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention‐deficit/hyperactivity disorder. This double‐blind, placebo‐ and moxifloxacin‐controlled, 3‐period crossover trial evaluated the effects of centanafadine (EB‐1020) and its metabolite (EB‐10601) on cardiac repolarization in 30 ...
Osman S. Turkoglu+3 more
wiley +1 more source
Stress protein responses in rat brain of PB-withdrawal syndrome
Yuri Okuno+6 more
openalex +1 more source
ERYTHROCYTE THIAMINE (Th) ESTERS: A MAJOR FACTOR OF THE ALCOHOL WITHDRAWAL SYNDROME OR A CANDIDATE MARKER FOR ALCOHOLISM ITSELF? [PDF]
Mauro Ceccanti+8 more
openalex +1 more source
Abstract Berzosertib is a small‐molecule ataxia telangiectasia and Rad3‐related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2‐period, open‐label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210 mg/m2 berzosertib containing approximately 3 µCi of [14C ...
Jayaprakasam Bolleddula+12 more
wiley +1 more source
415: Cross-Talk between Androgen Receptor and Prosaposin in Prostate Cancer and Stromal Cells Supports a Potential Mechanism for Antiandrogen Withdrawal Syndrome [PDF]
Shahriar Koochekpour+12 more
openalex +1 more source